INOpulse Nitric Oxide System Seen to Treat PH Patients with IPF and COPD Symptoms
COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension
The INOpulse nitric oxide delivery system met its primary Phase 2 clinical trial goal of increasing the blood-vessel volume of pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to its maker, Bellerophon Therapeutics. ... Read more